Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClouDr Group's ROE % for the quarter that ended in Dec. 2025 was -99.55%. ClouDr Group's PB Ratio for the quarter that ended in Dec. 2025 was 1.01.
ClouDr Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -98.56%.
ClouDr Group ROE % Adjusted to Book Value Related Terms
ClouDr Group ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for ClouDr Group's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:H3L vs MCK, COR, CAH: ROE % Adjusted to Book Value Comparison
For the Medical Distribution subindustry, ClouDr Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group ROE % Adjusted to Book Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where ClouDr Group's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -98.56% mean?
ClouDr Group (FRA:H3L) has a ROE % Adjusted to Book Value of -98.56% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ClouDr Group and its competitors.
Is ClouDr Group's ROE % Adjusted to Book Value too high?
ClouDr Group's current ROE % Adjusted to Book Value is -98.56%. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's ROE % Adjusted to Book Value compare to MCK and COR?
ClouDr Group's ROE % Adjusted to Book Value of -98.56% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Distribution company?
A good ROE % Adjusted to Book Value depends on the Medical Distribution industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ClouDr Group and its competitors. ClouDr Group's current ROE % Adjusted to Book Value is -98.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current ROE % Adjusted to Book Value of -98.56%. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current ROE % Adjusted to Book Value is -98.56%. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current ROE % Adjusted to Book Value is -98.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (FRA:H3L) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:H3L:
ROE % Adjusted to Book Value: -98.56%
GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for FRA:H3L
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3L has been successfully added to your 
